Endocrine News Podcast

The Endocrine Society’s chief professional and clinical affairs officer, Robert Lash, MD, talks with Griffin Rodgers, MD, director of the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases, and William Cefalu, MD, director of NIDDK’s Division of Diabetes, Endocrinology and Metabolic Disease. They talk about the institute’s mission, the months since Dr. Cefalu took over the division, and their interactions with professional organizations like the Endocrine Society. For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast.

According to the National Institutes of Health, more than two in five adults have obesity in the United States, and nearly one in three is overweight. To equip health care practitioners with the resources they need to treat patients with obesity, the Endocrine Society recently held its innaugual obesity fellows program, an exclusive, application-based, educational activity for current fellows. The program covered a wealth of information, and host Aaron Lohr talks with Amy Rothberg, MD, DABOM, program chair and a clinical professor of internal medicine at the University of Michigan’s School of Public Health. If you weren’t able to attend the fellows program, we have a free series of on-demand lectures available online, and those are accredited. With thanks to Lilly USA LLC and Novo Nordisk for making both the obesity fellows program and this podcast episode possible through an unrestricted, educational grant. Show notes, including a link to the Endocrine Society Learning Center for earning ABIM points and AMA PRA Category 1 credits, are available at https://www.endocrine.org/podcast/enp81-obesity-fellows-program — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, we learn about endocrine-disrupting chemicals known as perfluoroalkyl and polyfluoroalkyl substances (PFAS), which break down so slowly that they have been called “forever chemicals.” Where can PFAS be found? What exactly is their effect on human health? What are manufacturers doing to limit exposure, and is it enough? Host Aaron Lohr talks with Benson T. Akingbemi, PhD, professor of anatomy and developmental biology at Auburn University. Dr. Akingbemi and colleagues recently published an article on PFAS in the journal Endocrinology titled, “Legacy and Emerging Perfluoroalkyl and Polyfluoroalkyl Substances Regulate Steroidogenesis in the Male Gonad.” Show notes are available at https://www.endocrine.org/podcast/enp82-pfas — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

We all know that sleep is important, but sometimes we just don’t get enough. We also know the normal side effects from lack of sleep, but are there other, metabolic, and neuronendocrine effects from short sleep that we don’t know about. Host Aaron Lohr talks about this with Iris CM Pelsma, an academic researcher at Leiden University Medical Center in the Netherlands. She and her colleagues presented a study earlier this year, at ENDO 2023, titled, “Metabolic and Neuroendocrine Adaptability Following One Night of Partial Sleep Restriction in Dutch Males.” Show notes are available at https://www.endocrine.org/podcast/enp80-metabolic-and-neuroendocrine-effects-of-short-sleep — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for the treatment of osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.” Show notes are available at https://www.endocrine.org/podcast/enp73-a-robotic-teriparatide-pill-to-treat-osteoporosis — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast